期刊文献+

DNT细胞的扩增及其对胰腺癌Panc-1细胞的影响 被引量:2

Effects of ex vivo expanded DNT cells on growth of Panc-1 cells
下载PDF
导出
摘要 目的探讨TCR+CD3+CD4-CD8-(DNT)双阴T细胞对人胰腺癌细胞系Panc-1的影响。方法应用抗体吸附法扩增人外周血DNT细胞,采用流式细胞仪检测所得细胞表型,选择多组对照观察DNT细胞对裸鼠荷瘤的生长曲线和抑瘤率的影响,应用RT-PCR检测不同浓度DNT细胞与Panc-1细胞体外培养后Fas/FasL的表达情况。结果经过12 d左右的培养,每孔细胞数量可达1.0×106个以上。流式细胞仪鉴定细胞表型为CD3+CD4-CD8-。与阴性对照组比较,实验组和阳性对照组对裸鼠荷瘤的肿瘤生长曲线及抑瘤率的差异有统计学意义,实验组的抑瘤率达44.75%。DNT细胞与胰腺癌细胞共培养后,胰腺癌细胞在mRNA水平的Fas表达量明显上升,差异有统计学意义;FasL表达略有下调,差异无统计学意义。结论 DNT细胞能抑制胰腺癌Panc-1细胞株增殖,Fas/FasL途径为其作用机制之一。 Objective To find out the effects of CD3^+ CD^4- CD8^- double negative T cells on suppression of pancreatic cancer in vitro and vivo. Methods DNT cells were expanded in vivo based on a protocol of antibody absorption, and the cell surface molecules were identified by flow cytometry. The growth curve and inhibitory rate of Panc-1 xenografted nude mice was observed. The expression of Fas/FasL of Panc-1 with different concentrations of DNT cells was detected by RT-PCR. Results A mean of 1.0 × 10^6/hole was obtained after 12 day' culture of the expanded cells. In animal experiments, both DNT cells and celecoxib could suppress the growth curve and inhibitory rate of Panc-1 xenografted nude mice, and differences had statistical significance. After 48 hours co-culture with DNT cells, the Fas up-regulated their expressions, with statistically significant differences, while the FasL down-regulated their expressions. Conclusion DNT ceils could inhibit the growth of Panc-1, with Fas/FasL pathway as one of the important mechanisms.
出处 《安徽医科大学学报》 CAS 北大核心 2013年第3期228-232,共5页 Acta Universitatis Medicinalis Anhui
基金 国家自然科学基金(编号:81071985) 安徽省国际科技合作项目(编号:1008070303) 安徽省教育厅自然科学研究项目(编号:KJ2008A164)
关键词 胰腺癌 DNT细胞 免疫治疗 pancreatic cancer double negative T cell immunotherapy
  • 相关文献

参考文献12

  • 1Merims S,Li X,Joe B. Anti-leukemia effect of ex vivo expanded DNT cells from AML patients:a potential novel autologous T-cell adoptive immunotherapy[J].Leukemia:Official Journal of the Leukemia Society of America,Leukemia Research Fund,U.K,2011,(09):1415-1422.
  • 2Dokouhaki P,Han M,Joe B. Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells:A new approach[J].Cancer Letters,2010,(01):126-136.
  • 3Ford M S,Chen W,Wong S. Peptide-activated double-negative T cells can prevent autoimmune type-1 diabetes development[J].European Journal of Immunology,2007,(08):2234-2241.doi:10.1002/eji.200636991.
  • 4Ford McIntyre M S,Young K J,Gao J. Cutting edge:in vivo trogocytosis as a mechanism of double negative regulatory T cell-mediated antigen-specific suppression[J].Journal of Immunology,2008,(04):2271-2275.
  • 5Young K J,Kay L S,Phillips M J. Antitumor activity mediated by double-negative T cells[J].Cancer Research,2003,(22):8014-8021.
  • 6陈炯,杜敏,李文波,雷春,汤厚阔,翟志敏,李庆.胰腺癌患者外周血CD4^-CD8^-T细胞的检测及其临床意义[J].中华实验外科杂志,2007,24(12):1528-1529. 被引量:7
  • 7陈炯,杜敏,李文波,雷春,杨兵,汤厚阔,翟志敏,马金良,李庆.胰腺癌患者外周血CD4^-CD8^-T细胞与IL-4、IFN-γ的关系[J].中华外科杂志,2009,47(13):995-998. 被引量:9
  • 8Zhang Z X,Yang L,Young K J. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression[J].Nature Medicine,2000,(07):782-789.
  • 9Khan Q,Penninger J M,Yang L. Regulation of apoptosis in mature alphabeta CD-4CD-8 antigen specific suppressor T cell clones[J].Journal of Immunology,1999,(10):5860-5867.
  • 10Voelkl S,Gary R,Mackensen A. Characterization of the immunoregulatory function of human TCR-αβ+CD-4 CD-8 double-negative T cells[J].European Journal of Immunology,2011,(03):739-748.

二级参考文献17

共引文献19

同被引文献14

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 [ J] CA Cancer J Clin, 2012,62( 1 ) :10 -29.
  • 2Jablonska E, Jablonski J, Marcinczyk M, et al. The release of sol- uble forms of TRAIL and DR5 by neutrophils of oral cavity cancer patients [ J]. Folia Histochem Cytobiol,2008,46 (2) : 177 - 83.
  • 3Tanaka H, ho T, Kyo T, et al. Treatment with IFNalpha in vivo up-regulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients [ J ]. Eur J Haematol, 2007,78 (5) :389 - 98.
  • 4Sobin L H, Wittekind C. UICC-TNM classification of malignant tumours[ M]. 6th ed. New York: Wiley-Lissm,2002.
  • 5Merims S, Li X, Joe B, et al. Anti-leukemia effect of ex vivo ex- panded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy [ J ]. Leukemia, 2011,25 ( 9 ) : 1415 -22.
  • 6Dokouhaki P, Han M, Joe B, et al. Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach [ J]. Cancer Lett,2010, 297 ( 1 ) : 126 - 36.
  • 7Livak K J, Schmittgen T D. Analysis of relative gene expression data using real-time quantitative PCR and the 2 ( - Delta Delta C (T)) method [J]. Methods,2001, 25(4) :402 -8.
  • 8Todaro M, D'Asaro M, Caccamo N, et al. Efficient killing of hu- man colon cancer stem cells by gammadelta T lymphocytes [ J ]. J Immunol,2009,182 ( 11 ) :7287 - 96.
  • 9Dokouhaki P, Schuh N W, Joe B, et al. NKG2D regulates pro- duction of soluble TRAIL by ex vivo expanded human 3^st T cells [ J]. Eur J Immunol, 2013,43 (12) :3175 - 82.
  • 10Spierings D C, de Vries E G, Vellenga E, et al. Tissue distribu- tion of the death ligand TRAIL and its receptors [J]. J Histochem Cytochem,2004,52(6) :821 -31.

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部